(1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-d]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE HYDROCHLORIDE Russian patent published in 2015 - IPC C07D487/04 A61K31/519 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to several versions of crystalline forms of formula compound, which possesses properties of inhibitor of E1-, in particular NAE-activating enzyme. Compound can be used in treatment of cancer, where cancer is represented by leukaemia or lymphoma, acute myeloblastic leucosis (AML), myelodysplastic syndrome (MDS), chronic myelogenous leucosis (CML), acute lymphoblastic leucosis (ALL), chronic lymphocytic leucosis (CLL),Hodgkin's disease, Hodgkin's lymphoma, lymphoma of B-cells, lymphoma of T-cells, multiple myeloma (MM), Waldenstrom's macroglobulinemia or myeloproliferative syndrome. Each crystalline form is characterised by diagram of powder X-ray diffraction (PXD), data of differential scanning calorimetry (DSC) and data of thermographic analysis (TGA). Data on water-solubility (about 7.8 mg/ml) for crystalline form 1 are also given.

EFFECT: crystalline forms of hydrochloride possess improved properties in comparison with amorphous form of base and potassium salt.

35 cl, 15 dwg, 9 tbl, 10 ex